GlassScriptPhysician profile
Thomas S Kang
NPI 1588766604
$6,439.61
in general payments reported to CMS, 2019-2025
25 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what a typical Otology & Neurotology provider received nationally (typical 2025 total: $411).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,254 · 2020: $325 · 2021: $1,223 · 2022: $1,480 · 2023: $517 · 2024: $442 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,158.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,355.07 | 2019-2025 | Scopis Ent, Xpress Loprofile, Core |
| Acclarent, INC | $745.80 | 2019-2024 | Trudi Nav Cable, Acclarent Aera |
| Aerin Medical INC. | $591.14 | 2019-2025 | |
| Genzyme Corporation | $556.31 | 2019-2025 | |
| Glaxosmithkline, LLC. | $538.80 | 2021-2025 | Nucala |
| Medtronic, INC. | $457.95 | 2021-2025 | Interstim, Sinuva |
| Regeneron Healthcare Solutions, INC. | $340.80 | 2020-2025 | Dupixent |
| Merz North America, INC. | $295.40 | 2021 | |
| Optinose US, INC. | $248.35 | 2019-2021 | |
| Medical Device Business Services, INC. | $235.25 | 2019 | |
| Intersect Ent, INC. | $194.10 | 2019-2020 | |
| Xoran Technologies LLC | $162.94 | 2019 | |
| Inspire Medical Systems, INC. | $144.70 | 2022-2023 | Inspire |
| Arrinex, INC. | $140.76 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2025 | Tezspire |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $120.34 | 2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $29.85 | 2025 | Voquezna |
| Hill Dermaceuticals, INC. | $26.46 | 2025 | Tolak |
| Medtronic USA, INC. | $23.02 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $22.68 | 2023 | Seglentis |
| Sanofi-Aventis U.S. LLC | $21.38 | 2020 | |
| Amgen INC. | $21.04 | 2025 | Tezspire |
| Neurent Medical Limited | $14.65 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Karl Storz Endoscopy-America | $14.04 | 2021 | |
| Integra Lifesciences Corporation | $13.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.